BALTIMORE, Jan. 22,
2024 /PRNewswire/ -- Haystack Oncology, a Quest
Diagnostics (NYSE: DGX) company and developer of best-in-class
personalized MRD technology (Haystack MRD™), has entered a research
collaboration with TriSalus Life Sciences to evaluate therapeutic
response and provide molecular insights in connection with the
clinical development of TriSalus' SD-101, an investigational class
C toll-like receptor-9 (TLR9) agonist. SD-101 is delivered via
hepatic arterial infusion or pancreatic retrograde venous infusion
in their phase 1 and 1b clinical
trials using their proprietary Pressure-Enabled Drug Delivery™
(PEDD™) to overcome the challenges associated with intratumoral
pressure for patients diagnosed with hepatocellular carcinoma,
intrahepatic cholangiocarcinoma, and pancreatic adenocarcinoma.
![Quest Diagnostics Incorporated logo. (PRNewsFoto/Quest Diagnostics Incorporated) Quest Diagnostics Incorporated logo. (PRNewsFoto/Quest Diagnostics Incorporated)](https://mma.prnewswire.com/media/200883/quest_diagnostics_incorporated_logo_logo.jpg)
"Haystack MRD is specifically designed and developed to
accurately detect circulating tumor DNA (ctDNA) with unparalleled
sensitivity in patients with low tumor burden and in clinically
challenging cancer types," said Dan
Edelstein, Vice President and General Manager, Haystack
Oncology. "Haystack MRD's sensitivity enables clinical
investigators to closely follow molecular response and measure
early evidence of treatment efficacy. We're excited to collaborate
with TriSalus to support the clinical development of SD-101 in
combination with their unique therapy delivery technology, which
aims to overcome challenges associated with treating liver and
pancreatic tumors."
Hepatocellular carcinoma is the most common form of liver
cancer. Intrahepatic cholangiocarcinoma is cancer that occurs in
the parts of the bile ducts that are within the liver. Pancreatic
adenocarcinoma is the most common form of pancreatic cancer.
"A significant challenge in the development of immunotherapies
for liver and pancreatic tumors is early measurement of response to
treatment. Conventional imaging response assessment methods may be
misleading in certain situations, and accurate ctDNA assays offer
the potential to identify meaningful biologic activity in difficult
to treat cancers," says Steven Katz,
MD, Chief Medical Officer of TriSalus Life Sciences. "We are
thrilled to work with Haystack in pursuit of our mission to develop
better therapeutic options for patients with liver and pancreatic
tumors."
About Haystack Oncology
Haystack Oncology represents
the culmination of over 20 years of technical and clinical
development in liquid biopsy technologies by cancer genomics
pioneers at Johns Hopkins School of
Medicine. The company, a wholly owned subsidiary of Quest
Diagnostics, developed Haystack MRD™, a next generation tumor
informed approach for the measurement of minimal residual disease.
Haystack MRD uses an error-corrected ctDNA technology to detect
down to one ctDNA molecule in a million. Haystack Oncology works
with biopharmaceutical companies to accelerate and improve
efficiency of clinical development programs and advance important
therapeutics to global markets, from early phase clinical
development to companion diagnostics. Haystack MRD (Research
Use Only) is CLIA certified in the US and is available for
biopharmaceutical clinical development in laboratories located in
Baltimore, Maryland, Hamburg, Germany and Helsinki, Finland. Learn more at
haystackoncology.com.
About Quest Diagnostics
Quest Diagnostics empowers
people to take action to improve health outcomes. Derived from the
world's largest database of clinical lab results, our diagnostic
insights reveal new avenues to identify and treat disease, inspire
healthy behaviors and improve health care management. Quest
annually serves one in three adult Americans and half the
physicians and hospitals in the United
States, and our nearly 50,000 employees understand that, in
the right hands and with the right context, our diagnostic insights
can inspire actions that transform lives.
www.QuestDiagnostics.com.
About TriSalus
TriSalus is an oncology company
integrating immunotherapy with disruptive delivery technology to
transform the treatment paradigm for patients with cancer.
TriSalus' proprietary platform approach addresses immune
dysfunction in liver and pancreatic tumors by combining its highly
effective drug delivery technology with immunotherapeutics.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/haystack-oncology-developer-of-haystack-mrd-and-trisalus-life-sciences-collaborate-in-connection-with-the-clinical-development-of-trisalus-tlr9-agonist-in-hepatocellular-carcinoma-intrahepatic-cholangiocarcinoma-and-pancreat-302039834.html
SOURCE Quest Diagnostics